IDEAS home Printed from https://ideas.repec.org/a/wly/hlthec/v11y2002i4p285-299.html
   My bibliography  Save this article

Prenatal screening for cystic fibrosis: an economic analysis

Author

Listed:
  • Randi Nielsen
  • Dorte Gyrd‐Hansen

Abstract

Cystic fibrosis (CF) is the most common life‐shortening genetically transmitted disease in Denmark with a birth prevalence of 1 in 4700, resulting in 12–15 new cases of cystic fibroses annually. The aim of this study is to disclose the societal resource implications of introducing a population wide prenatal screening programme for cystic fibrosis in Denmark. The present analysis is limited to the monetary consequences of introducing a screening programme, where costs of screening are compared to the potential benefits measured in cost savings involved if births of CF patients are avoided. Screening costs in a Danish setting were estimated at DKK 2 771 262 (£231 438) per aborted affected fetus in the first screening round, stabilising at DKK 1 864 594 (£155 383) per aborted affected fetus at subsequent screening rounds. Comparing this figure with the estimated benefits of avoiding a CF case (DKK 2.1–4.4 million; £175 000–366 667) suggests that introducing a screening programme for cystic fibrosis will be net cost saving irrespective of the perspective of the analysis, assumptions on replacement children and method of estimating long‐term production gains/losses. Copyright © 2001 John Wiley & Sons, Ltd.

Suggested Citation

  • Randi Nielsen & Dorte Gyrd‐Hansen, 2002. "Prenatal screening for cystic fibrosis: an economic analysis," Health Economics, John Wiley & Sons, Ltd., vol. 11(4), pages 285-299, June.
    • Handle: RePEc:wly:hlthec:v:11:y:2002:i:4:p:285-299
    DOI: 10.1002/hec.652
    as

    Download full text from publisher

    File URL: https://doi.org/10.1002/hec.652
    Download Restriction: no
    File URL: https://libkey.io/10.1002/hec.652?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. David A. Asch & John C. Hershey & Michael L. Dekay & Mark V. Pauly & James P. Patton & M. Kathryn Jedrziewski & Frances Frei & Rose Giardine & Jeffrey A. Kant & Michael T. Mennuti, 1998. "Carrier Screening for Cystic Fibrosis," Medical Decision Making, , vol. 18(2), pages 202-212.
    2. David Meltzer, 1997. "Accounting for Future Costs in Medical Cost-Effectiveness Analysis," NBER Working Papers 5946, National Bureau of Economic Research, Inc.
    3. Johannesson, Magnus & Karlsson, Goran, 1997. "The friction cost method: A comment," Journal of Health Economics, Elsevier, vol. 16(2), pages 249-255, April.
    4. Meltzer, David, 1997. "Accounting for future costs in medical cost-effectiveness analysis," Journal of Health Economics, Elsevier, vol. 16(1), pages 33-64, February.
    5. Cam Donaldson & Phil Shackley & Mona Abdalla & Zosia Miedzybrodzka, 1995. "Willingness to pay for antenatal carrier screening for cystic fibrosis," Health Economics, John Wiley & Sons, Ltd., vol. 4(6), pages 439-452, November.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Muralikrishnan Radhakrishnan & Kees van Gool & Jane Hall & Martin Delatycki & John Massie, 2006. "Economic evaluation of cystic fibrosis screening: A Review of the literature, CHERE Working Paper 2006/6," Working Papers 2006/6, CHERE, University of Technology, Sydney.
    2. Fernando Antoñanzas & R. Rodríguez-Ibeas & M. Hutter & R. Lorente & C. Juárez & M. Pinillos, 2012. "Genetic testing in the European Union: does economic evaluation matter?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(5), pages 651-661, October.
    3. Jeremy D. Goldhaber-Fiebert & Margaret L. Brandeau, 2015. "Evaluating Cost-effectiveness of Interventions That Affect Fertility and Childbearing," Medical Decision Making, , vol. 35(7), pages 818-846, October.
    4. Angelis, Aris & Tordrup, David & Kanavos, Panos, 2015. "Socio-economic burden of rare diseases: A systematic review of cost of illness evidence," Health Policy, Elsevier, vol. 119(7), pages 964-979.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Werner B.F. Brouwer & Frans F.H. Rutten, 2003. "The missing link: on the line between C and E," Health Economics, John Wiley & Sons, Ltd., vol. 12(8), pages 629-636, August.
    2. Brouwer, Werner B. F. & Koopmanschap, Marc A., 2000. "On the economic foundations of CEA. Ladies and gentlemen, take your positions!," Journal of Health Economics, Elsevier, vol. 19(4), pages 439-459, July.
    3. Bengt Liljas, 2010. "On the welfare theoretic foundation of cost-effectiveness analysis—the case when survival is not affected," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(1), pages 5-13, February.
    4. Magnus Johannesson & David Meltzer, 1998. "Editorial: Some reflections on cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 7(1), pages 1-7, February.
    5. Bengt Liljas, 2011. "Welfare, QALYs, and costs – a comment," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 68-72, January.
    6. Douglas Lundin & Joakim Ramsberg, 2008. "On survival consumption costs – a reply to Nyman," Health Economics, John Wiley & Sons, Ltd., vol. 17(2), pages 293-297, February.
    7. John A. Nyman, 2006. "More on survival consumption costs in cost‐utility analysis," Health Economics, John Wiley & Sons, Ltd., vol. 15(3), pages 319-322, March.
    8. Kenneth Manton & Kenneth Land, 2000. "Active life expectancy estimates for the U.S. elderly population: A multidimensional continuous-mixture model of functional change applied to completed Cohorts, 1982–1996," Demography, Springer;Population Association of America (PAA), vol. 37(3), pages 253-265, August.
    9. Stefan Felder, 2006. "Lebenserwartung, medizinischer Fortschritt und Gesundheitsausgaben: Theorie und Empirie," Perspektiven der Wirtschaftspolitik, Verein für Socialpolitik, vol. 7(s1), pages 49-73, May.
    10. Ernst R. Berndt & David M. Cutler & Richard Frank & Zvi Griliches & Joseph P. Newhouse & Jack E. Triplett, 2001. "Price Indexes for Medical Care Goods and Services -- An Overview of Measurement Issues," NBER Chapters, in: Medical Care Output and Productivity, pages 141-200, National Bureau of Economic Research, Inc.
    11. Pieter H. M. van Baal & Talitha L. Feenstra & Johan J. Polder & Rudolf T. Hoogenveen & Werner B. F. Brouwer, 2011. "Economic evaluation and the postponement of health care costs," Health Economics, John Wiley & Sons, Ltd., vol. 20(4), pages 432-445, April.
    12. Kenkel, Don, 1997. "On valuing morbidity, cost-effectiveness analysis, and being rude," Journal of Health Economics, Elsevier, vol. 16(6), pages 749-757, December.
    13. Michael E. Darden & Robert Kaestner, 2022. "Smoking, selection, and medical care expenditures," Journal of Risk and Uncertainty, Springer, vol. 64(3), pages 251-285, June.
    14. David M. Cutler & Ellen Meara, 1998. "The Medical Costs of the Young and Old: A Forty-Year Perspective," NBER Chapters, in: Frontiers in the Economics of Aging, pages 215-246, National Bureau of Economic Research, Inc.
    15. Mark Sculpher & David Torgerson & Ron Goeree & Bernie O'Brien, 1999. "A critical structured review of economic evaluations of interventions for the prevention and treatment of osteoporosis," Working Papers 169chedp, Centre for Health Economics, University of York.
    16. Joshua Graff Zivin, 2001. "Cost‐effectiveness analysis with risk aversion," Health Economics, John Wiley & Sons, Ltd., vol. 10(6), pages 499-508, September.
    17. Basu, Anirban, 2015. "Welfare implications of learning through solicitation versus diversification in health care," Journal of Health Economics, Elsevier, vol. 42(C), pages 165-173.
    18. Blomqvist, Ake, 2002. "Defining the value of a statistical life: a comment," Journal of Health Economics, Elsevier, vol. 21(1), pages 169-175, January.
    19. Zon, Adriaan van & Muysken, Joan, 2003. "Health as a Principal Determinant of Economic Growth," Research Memorandum 024, Maastricht University, Maastricht Economic Research Institute on Innovation and Technology (MERIT).
    20. Philipson Tomas J & Jena Anupam B, 2006. "Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs," Forum for Health Economics & Policy, De Gruyter, vol. 9(2), pages 1-33, January.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:wly:hlthec:v:11:y:2002:i:4:p:285-299. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www3.interscience.wiley.com/cgi-bin/jhome/5749 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.